- Trials with a EudraCT protocol (171)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
171 result(s) found for: Neovascularization.
Displaying page 8 of 9.
EudraCT Number: 2019-003851-12 | Sponsor Protocol Number: 20968 | Start Date*: 2020-06-25 | |||||||||||
Sponsor Name:Bayer AG | |||||||||||||
Full Title: Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration | |||||||||||||
Medical condition: Neovascular Age-Related Macular Degeneration | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) LT (Completed) LV (Completed) PT (Completed) EE (Completed) AT (Completed) FR (Completed) SK (Completed) BG (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001961-20 | Sponsor Protocol Number: FYB201-C2015-01-P3 | Start Date*: 2015-11-24 | ||||||||||||||||
Sponsor Name:Bioeq GmbH | ||||||||||||||||||
Full Title: Efficacy and safety of the biosimilar ranibizumab FYB201 in comparison to Lucentis in patients with neovascular age-related macular degeneration (COLUMBUS-AMD) | ||||||||||||||||||
Medical condition: Subfoveal neovascular age-related macular degeneration | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: CZ (Completed) AT (Completed) DE (Completed) HU (Completed) ES (Completed) FR (Completed) GB (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-000681-42 | Sponsor Protocol Number: CoRaLa_II | Start Date*: 2020-08-24 | ||||||||||||||||
Sponsor Name:Justus-Liebig University Gießen | ||||||||||||||||||
Full Title: Long-term need of ranibizumab injections with or without early targeted peripheral laser photocoagulation for treatment of macular edema due to central retinal vein occlusion | ||||||||||||||||||
Medical condition: Macular edema due to central retinal vein occlusion | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Trial now transitioned) AT (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005364-57 | Sponsor Protocol Number: HLX04-O-wAMD | Start Date*: 2021-04-06 | |||||||||||
Sponsor Name:Shanghai Henlius Biotech. Inc. | |||||||||||||
Full Title: A Phase 3, Two-part (Open-label Followed by Randomized Double-masked Active Controlled) Study to Compare the Efficacy and Safety of HLX04-O Administered by Intravitreal Injection with ranibizumab i... | |||||||||||||
Medical condition: Wet Age-related Macular Degeneration (wAMD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Completed) HU (Completed) CZ (Prohibited by CA) PL (Completed) ES (Ongoing) SK (Completed) BG (Completed) DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-006358-86 | Sponsor Protocol Number: ATG003-201 | Start Date*: 2007-04-27 | |||||||||||
Sponsor Name:CoMentis, Inc., USA | |||||||||||||
Full Title: A PHASE II RANDOMIZED, DOUBLE-MASKED, STUDY COMPARING THE SAFETY AND EFFICACY OF ATG003 (MECAMYLAMINE HCL) 1.0% and 0.3% OPHTHALMIC SOLUTIONS TO PLACEBO IN PATIENTS WITH NEOVASCULAR ("WET") AGE-REL... | |||||||||||||
Medical condition: Neovascular ("wet") Age-related Macular Degeneration (NV- AMD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-004721-23 | Sponsor Protocol Number: VIBERA | Start Date*: 2007-11-14 | |||||||||||
Sponsor Name:Klinikum Bremen-Mitte gGmbH | |||||||||||||
Full Title: Prevention of vision loss in patients with age-related neovascular macular degeneration by intravitreal injection of bevacizumab and ranibizumab in a typical outpatient setting | |||||||||||||
Medical condition: age-related neovascular macular degeneration | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-006014-18 | Sponsor Protocol Number: 1419 | Start Date*: 2005-12-15 | |||||||||||
Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI | |||||||||||||
Full Title: Macular structure and function after intravitreal injection of bevacizumab for wet macular degeneration a interventional study. | |||||||||||||
Medical condition: Macular degeneration | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-004292-35 | Sponsor Protocol Number: 06NB37 | Start Date*: 2007-03-08 | |||||||||||
Sponsor Name:Kings College Hospital NHS Foundation Trust | |||||||||||||
Full Title: A pillot study to examine the safety and efficacy of intravitreal ranubizimab/dexamethasone administration and oral minocycline in addition to Visudyne (verteporfin) photdynamic therapy for subfove... | |||||||||||||
Medical condition: Age related macular degeneration | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001262-28 | Sponsor Protocol Number: MSC-TENDO-2015 | Start Date*: 2017-08-21 | |||||||||||
Sponsor Name:Institut de Terapia Regenerativa Tissular S.L. (ITRT) | |||||||||||||
Full Title: Treatment of Refractory Patellar Tendinopathy with MSV *. Comparative study with P-PRP *MSV are bone marrow autologous mesenchymal stem cells, selected and cultured under Good manufacturing Practic... | |||||||||||||
Medical condition: Patients diagnosed with patellar tendinopathy with a minimum of 4 months evolution and have presented two acute episodes, refractory to standard treatments present a gap equal or greater than 3 mm ... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-003853-97 | Sponsor Protocol Number: PNB1 | Start Date*: 2007-10-18 | |||||||||||
Sponsor Name:Central Manchester University Hospitals NHS Foundation Trust | |||||||||||||
Full Title: A 23-month randomised, masked, prospective phase IV study assessing the safety and efficacy of two alternative treatment regimes using Bevacizumab (AvastinTM) to treat patients with subfoveal and j... | |||||||||||||
Medical condition: "wet" or "exudative" age-related macular degeneration (AMD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-014280-38 | Sponsor Protocol Number: 09OY006 | Start Date*: 2009-11-13 | |||||||||||
Sponsor Name:Nottingham University Hospitals NHS Trust | |||||||||||||
Full Title: A randomised controlled trial of standard and low dose Avastin® for Neovascular Macular Degeneration in the East Midlands | |||||||||||||
Medical condition: Neovascular ("wet") age-related macular degeneration | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-005684-26 | Sponsor Protocol Number: Version_1_10072006 | Start Date*: 2007-09-06 | |||||||||||||||||||||
Sponsor Name:Universitätsklinik für Augenheilkunde und Optometrie, AKH Wien | |||||||||||||||||||||||
Full Title: Identification and Quantification of Cytokines in Anti-VEGF Therapy and Genetic Risk Factors in Exsudative Age-related Macular Degeneration | |||||||||||||||||||||||
Medical condition: Exsudative age-related macular degeneration (AMD), cataract, macular pucker | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: AT (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-004952-12 | Sponsor Protocol Number: 4429-202 | Start Date*: 2013-04-05 | |||||||||||
Sponsor Name:Acucela Inc. | |||||||||||||
Full Title: A Phase 2b/3 Multicenter, Randomized, Double-Masked, Dose-Ranging Study Comparing the Efficacy and Safety of Emixustat Hydrochloride (ACU-4429) with Placebo for the Treatment of Geographic Atrophy ... | |||||||||||||
Medical condition: Geographic atrophy associated with dry age-related macular degeneration | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-017429-21 | Sponsor Protocol Number: ZAPA-01 | Start Date*: 2010-03-22 | |||||||||||
Sponsor Name:Miguel Ángel Zapata. Oftalmología. Hospital vall d'Hebron | |||||||||||||
Full Title: ENSAYO CLÍNICO, ABIERTO, DE SEGURIDAD Y EFICACIA DE ADALIMUMAB INTRAVÍTREO EN PACIENTES CON NEOVASCULARIZACIÓN COROIDEA SECUNDARIA A DEGENERACIÓN MACULAR ASOCIADA A LA EDAD EN PACIENTES NO RESPONDE... | |||||||||||||
Medical condition: Degeneración macular asociada a la edad en su forma exudativa | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000946-37 | Sponsor Protocol Number: 2019-06 | Start Date*: 2020-11-30 | |||||||||||
Sponsor Name:Assistance Publique-Hôpitaux de Marseille | |||||||||||||
Full Title: Molecular imaging exploration of ocular angiogenic activity and evaluation of its relevance in the therapeutic follow-up of AMD patients. | |||||||||||||
Medical condition: Age-related macular degeneration | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-000765-20 | Sponsor Protocol Number: ANTIVEGFVEP | Start Date*: 2015-11-27 | |||||||||||||||||||||
Sponsor Name:Kuopion yliopistollinen sairaala/silmätautien poliklinikka | |||||||||||||||||||||||
Full Title: The Effect of Intravitreal Bevacizumab Injections in Patients with Macular Oedema Caused by AMD, CRVO or DME on the Plasticity of Nerves Studied by Visual Evoked Potentials | |||||||||||||||||||||||
Medical condition: Wet age-related macular degeneration, diabetic macular edema, central retinal vein occlusion | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: FI (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-003261-14 | Sponsor Protocol Number: R01 | Start Date*: 2006-08-28 | |||||||||||
Sponsor Name:Retinaklinikken Omnia | |||||||||||||
Full Title: A randomized pilot study comparing the safety and efficacy of intravireal triamcinolone acetonide given 7 days prior to or after Photodynamic therapy with Visudyne in patients with subfoveal choroi... | |||||||||||||
Medical condition: Patients with age-related macular degeneration | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000168-32 | Sponsor Protocol Number: NL51705.000.15 | Start Date*: 2016-07-13 | |||||||||||
Sponsor Name:University Medical Center Utrecht | |||||||||||||
Full Title: Mesenchymal stem cells for Angiogenesis and Neovascularization in digital Ulcers of Systemic sclerosis | |||||||||||||
Medical condition: systemic sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-000120-33 | Sponsor Protocol Number: BAY86-5321/16598 | Start Date*: 2015-08-26 | ||||||||||||||||
Sponsor Name:Bayer HealthCare AG | ||||||||||||||||||
Full Title: An open-label, randomized, active-controlled, parallel-group, Phase-3b study of the efficacy, safety, and tolerability of 2 mg aflibercept administered by intravitreal injections using two differen... | ||||||||||||||||||
Medical condition: Neovascular Age-Related Macular Degeneration (nAMD) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: HU (Completed) CZ (Completed) SK (Completed) PT (Completed) LT (Completed) AT (Completed) GB (GB - no longer in EU/EEA) ES (Completed) DE (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-003651-42 | Sponsor Protocol Number: AVT06-GL-C01 | Start Date*: 2022-04-14 | |||||||||||
Sponsor Name:Alvotech Swiss AG | |||||||||||||
Full Title: A Randomized, Double-masked, Parallel-group, Multicenter Clinical Study to Evaluate the Efficacy and Safety of AVT06 Compared with EU-Eylea® in Subjects with Neovascular (wet) Age related Macular D... | |||||||||||||
Medical condition: Neovascular (wet) Age-related Macular Degeneration | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Completed) SK (Completed) CZ (Completed) HU (Completed) BG (Completed) LT (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
